EL7.AI
StocksMedium•26 March 2026•
1 min read

Abbott Expands Chronic Care Portfolio with $23B Exact Sciences Deal and Positive Libre Data

Key Facts

1Abbott Laboratories completed the acquisition of Exact Sciences for approximately $23 billion to expand its presence in cancer diagnostics.
2New clinical trial data indicates that the FreeStyle Libre system improves glucose control for Type 2 diabetes patients using basal insulin.

Abbott Laboratories has finalized its acquisition of Exact Sciences in a deal valued at approximately $23 billion, marking a significant expansion into the cancer diagnostics market. This strategic move aligns with the company's broader focus on long-term chronic disease management and prevention. Simultaneously, Abbott released positive clinical trial data for its flagship FreeStyle Libre glucose monitoring system. The results demonstrate that the system significantly improves glucose control for Type 2 diabetes patients utilizing basal insulin. These developments underscore Abbott's commitment to strengthening its leadership in the medical technology sector. Analysts view the combination of a major M&A deal and strong product data as a bullish signal for the company's long-term growth trajectory.